-
Mashup Score: 16SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy - 10 month(s) ago
Objectives The protective role of sodium glucose cotransporter 2 (SGLT2) inhibitors in renal outcomes has been revealed by large cardiovascular outcome trials among patients with type 2 diabetes. However, the effect of SGLT2 inhibitors on lupus nephritis (LN) and its underlying mechanisms remain unknown. Methods We applied empagliflozin treatment to lupus-prone MRL/ lpr mice to explore the renal protective potential of SGLT2 inhibitors. An SGLT2 knockout monoclonal podocyte cell line was generated using the CRISPR/Cas9 system to examine the cellular and molecular mechanisms. Results In MRL/ lpr mice treated with empagliflozin, the levels of mouse anti-dsDNA IgG-specific antibodies, serum creatinine and proteinuria were markedly decreased. For renal pathology assessment, both the glomerular and tubulointerstitial damages were lessened by administration of empagliflozin. The levels of SGLT2 expression were increased and colocalised with decreased synaptopodin in the renal biopsy samples
Source: ard.bmj.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 2The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer: - 10 month(s) ago
Abstract Background Sodium glucose cotransporter-2 inhibitors (SGLT2is) are hypothesized to reduce the risk of anthracycline-associated cardiotoxicity. Objectives This study sought to determine the…
Source: www.jacc.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Top news June 2023: FDA approvals, updates from NLA and more - 11 month(s) ago
Healio | Cardiology Today has compiled a list of the top headlines in cardiology of June 2023.Readers were most interested in the FDA approvals of colchicine 0.5 mg, IV ferric carboxymaltose and mavacamten for various CV indications; updates from the National Lipid Association Scientific Sessions and Heart in Diabetes CME Conference; and more.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0SGLT2 Inhibitors May Improve CV Outcomes in Select Populations, Meta-Analysis Suggests - 11 month(s) ago
A new meta-analysis suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors can improve clinical outcomes in patients with heart failure (HF), type 2 diabetes mellitus (T2DM) and chronic kidne
Categories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Meta-analysis confirms benefits of SGLT2 inhibitors in various high-risk populations - 11 month(s) ago
SGLT2 inhibitors reduce risk for CV death and HF events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology.The researchers conducted a meta-analysis of 13 trials of SGLT2 inhibitors vs. placebo in 90,413 patients with HF, type 2 diabetes and/or chronic kidney disease (CKD).
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism - Nature Reviews Cardiology - 12 month(s) ago
In this Review, Packer summarizes the latest advances in our understanding of the mechanisms that underlie the benefits of sodium–glucose cotransporter 2 (SGLT2) inhibitors in heart failure, identifies specific pathways that are likely to mediate a direct effect of SGLT2 inhibitors on cardiomyocytes and proposes a novel conceptual framework that explains the findings from experimental studies and…
Source: NatureCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0SGLT2 inhibitors may reduce cancer risks among adults with diabetes - 12 month(s) ago
Adults with diabetes who use SGLT2 inhibitors have lower risks for developing most types of cancer compared with nonusers, though the risk for pancreatic cancer is higher among SGLT2 users, according to data from researchers in Taiwan. “Recently, novel antidiabetic agents with SGLT2 inhibitors were introduced and several pluripotent effects were proposed,” Wei-Syun Hu, MD, PhD,
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0SGLT2 inhibition could lower stroke risk in those with diabetes plus atrial fibrillation - 1 year(s) ago
SGLT2 inhibition was associated with reduced 5-year risk for stroke among patients with concomitant atrial fibrillation and diabetes, according to a study in the Journal of the American Heart Association. “From the animal studies, SGLT2 inhibitors could decrease oxidative stress in cardiomyocytes, reverse myocardial remodeling and reduce electronic alterations. These pleiotropic effects of
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Recent developments of interest in cardiovascular medicine
Source: www.medpagetoday.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study. “In indicated patients, SGLT2 inhibitors should be used early in the disease process to modify cardiorenal risk and improve long-term outcomes,” Healio | Cardiology Today Editorial Board
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
Empagliflozin treatment to #lupus prone MRL/lpr mice to explore renal protective potential of #SGLT2 inhibitors. The SGLT2 inhibitor empagliflozin alleviated #podocyte injury by attenuating inflammation & enhanced autophagy by reducing mTORC1 activity. https://t.co/9EJDG0lOph https://t.co/zlaNSW5MJu